Elvia Cowan - 01 Jan 2023 Form 3 Insider Report for Vaxcyte, Inc. (PCVX)

Role
SVP, Finance and Principal Accounting Officer
Signature
Elvia Cowan, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
01 Jan 2023
Net transactions value
$0
Form type
3
Filing time
04 Jan 2023, 15:33:53 UTC
Next filing
03 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PCVX Common Stock 0 01 Jan 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PCVX Stock Option (Right to Buy) 01 Jan 2023 Common Stock 140,000 $25.92 Direct F1
holding PCVX Stock Option (Right to Buy) 01 Jan 2023 Common Stock 15,000 $47.95 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the shares subject to the option shall vest on July 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F2 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

Remarks:

SVP, Finance and Principal Accounting Officer